Cravath’s New York Office Moves to Two Manhattan West
Virginia M. Anderson represents clients in connection with public and private securities offerings and other financing transactions, general corporate matters and mergers and acquisitions. She is a member of the Venture Capital & Growth Equity Practice, where she frequently represents venture capital‑backed companies and investors, as well as other growth‑stage companies and investors, in financing transactions and other matters throughout their lifecycles.
Her practice includes representing companies on initial public offerings and advising them on IPO readiness. Ms. Anderson also regularly represents investors, founders and special committees on various matters.
Notable work highlights include:
Ms. Anderson speaks and writes on legal topics relevant to emerging companies and venture capital. Her experience includes co-authoring the U.S. Law & Practice chapter of the Chambers Venture Capital Guide.
Ms. Anderson is from Nebraska. She received a B.A. summa cum laude from the University of Nebraska‑Lincoln in 2011 and a J.D. magna cum laude from Fordham University School of Law in 2016, where she was an Associate Editor of the Law Review and elected to the Order of the Coif.
Ms. Anderson joined Cravath in 2016 and was elected of counsel in 2023.
Her practice includes representing companies on initial public offerings and advising them on IPO readiness. Ms. Anderson also regularly represents investors, founders and special committees on various matters.
Notable work highlights include:
Ms. Anderson speaks and writes on legal topics relevant to emerging companies and venture capital. Her experience includes co-authoring the U.S. Law & Practice chapter of the Chambers Venture Capital Guide.
Ms. Anderson is from Nebraska. She received a B.A. summa cum laude from the University of Nebraska‑Lincoln in 2011 and a J.D. magna cum laude from Fordham University School of Law in 2016, where she was an Associate Editor of the Law Review and elected to the Order of the Coif.
Ms. Anderson joined Cravath in 2016 and was elected of counsel in 2023.
Deals & Cases
November 04, 2024
On November 4, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat, an investigational oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema, from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to $179 million, comprised of a $100 million upfront payment, up to $57 million in a sales-based milestone payment and a one-time $22 million optional payment. Additionally, the Trust is making a $5 million investment in KalVista’s common stock in a private placement transaction. Cravath is representing DRI Healthcare Trust in connection with the transaction.
Deals & Cases
July 17, 2023
On July 17, 2023, Proximus Group announced that it has signed a definitive agreement to acquire, through Proximus Opal, an approximately 58% interest in Route Mobile, a global company specialized in CPaaS services, from the founding shareholders of Route Mobile. As part of the agreement, some of the founding shareholders will reinvest in a minority stake in Proximus Opal, a subsidiary of the Proximus Group and the holding company of Telesign, Proximus’s U.S.‑based affiliate. Cravath, alongside Slaughter and May, AZB & Partners and NautaDutilh, is representing Route Mobile and its founding shareholders in connection with the transaction.
Deals & Cases
February 06, 2023
On February 6, 2023, RedHill Biopharma Ltd. (“RedHill”), a specialty biopharmaceutical company, announced the extinguishment of all RedHill’s debt obligations (including all principal, interest, revenue interest, prepayment premiums and exit fees) under the Credit Agreement between RedHill’s U.S. subsidiary RedHill Biopharma Inc. and HealthCare Royalty (“HCR”) dated February 23, 2020 (as amended) in exchange for the transfer of its rights in Movantik® (naloxegol) to Movantik Acquisition Co., an affiliate of HCR. Cravath is representing RedHill in connection with the transaction.
Deals & Cases
January 25, 2023
On January 24, 2023, WiseTech Global, developer of leading logistics execution software CargoWise, announced its acquisition of Envase Technologies (“Envase”), a leading provider of transport management system software for intermodal trucking, drayage (container haulage) and landside logistics in North America, in a transaction valued at $230 million. Envase is being acquired from private investment firm and supply chain investor Firmament, and a small number of other sellers. Cravath is representing WiseTech Global in connection with the transaction.
Publications
June 06, 2024
Cravath partner Nicholas A. Dorsey and of counsel Virginia M. Anderson co‑authored the U.S. Law & Practice chapter of the Chambers Venture Capital Guide, which was published in May 2024. The guide, which is part of the publisher’s Global Practice Guides series, provides the latest legal information on trends in the venture capital market; fund structures, economics and regulation; investments in VC companies; government subsidies and tax; and employee incentivization in the 20 jurisdictions covered. The U.S. Law & Practice chapter examined the increase in U.S. venture capital funding in artificial intelligence in 2023; the emergence of “down round” raises, bridge financing solutions and alternative financing solutions for companies that have faced financing challenges; typical venture capital fund structure in the U.S.; and more.
Firm News
November 20, 2023
On November 17, 2023, Virginia M. Anderson, D. Ana Choi, Christopher P. Davis, Janice T.P. Martindale, Flora Ng, Nicole M. Peles, Scott B. Reents and Kathryn‑Ann Stamm were named of counsels of the Firm and Jean Kearns and DongHwa Kim were named senior attorneys of the Firm, effective January 1, 2024.
Virginia M. Anderson represents clients in connection with public and private securities offerings and other financing transactions, general corporate matters and mergers and acquisitions. She is a member of the Venture Capital & Growth Equity Practice, where she frequently represents venture capital‑backed companies and investors, as well as other growth‑stage companies and investors, in financing transactions and other matters throughout their lifecycles.
Her practice includes representing companies on initial public offerings and advising them on IPO readiness. Ms. Anderson also regularly represents investors, founders and special committees on various matters.
Notable work highlights include:
Ms. Anderson speaks and writes on legal topics relevant to emerging companies and venture capital. Her experience includes co-authoring the U.S. Law & Practice chapter of the Chambers Venture Capital Guide.
Ms. Anderson is from Nebraska. She received a B.A. summa cum laude from the University of Nebraska‑Lincoln in 2011 and a J.D. magna cum laude from Fordham University School of Law in 2016, where she was an Associate Editor of the Law Review and elected to the Order of the Coif.
Ms. Anderson joined Cravath in 2016 and was elected of counsel in 2023.
Her practice includes representing companies on initial public offerings and advising them on IPO readiness. Ms. Anderson also regularly represents investors, founders and special committees on various matters.
Notable work highlights include:
Ms. Anderson speaks and writes on legal topics relevant to emerging companies and venture capital. Her experience includes co-authoring the U.S. Law & Practice chapter of the Chambers Venture Capital Guide.
Ms. Anderson is from Nebraska. She received a B.A. summa cum laude from the University of Nebraska‑Lincoln in 2011 and a J.D. magna cum laude from Fordham University School of Law in 2016, where she was an Associate Editor of the Law Review and elected to the Order of the Coif.
Ms. Anderson joined Cravath in 2016 and was elected of counsel in 2023.
Deals & Cases
November 04, 2024
On November 4, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat, an investigational oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema, from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to $179 million, comprised of a $100 million upfront payment, up to $57 million in a sales-based milestone payment and a one-time $22 million optional payment. Additionally, the Trust is making a $5 million investment in KalVista’s common stock in a private placement transaction. Cravath is representing DRI Healthcare Trust in connection with the transaction.
Deals & Cases
July 17, 2023
On July 17, 2023, Proximus Group announced that it has signed a definitive agreement to acquire, through Proximus Opal, an approximately 58% interest in Route Mobile, a global company specialized in CPaaS services, from the founding shareholders of Route Mobile. As part of the agreement, some of the founding shareholders will reinvest in a minority stake in Proximus Opal, a subsidiary of the Proximus Group and the holding company of Telesign, Proximus’s U.S.‑based affiliate. Cravath, alongside Slaughter and May, AZB & Partners and NautaDutilh, is representing Route Mobile and its founding shareholders in connection with the transaction.
Deals & Cases
February 06, 2023
On February 6, 2023, RedHill Biopharma Ltd. (“RedHill”), a specialty biopharmaceutical company, announced the extinguishment of all RedHill’s debt obligations (including all principal, interest, revenue interest, prepayment premiums and exit fees) under the Credit Agreement between RedHill’s U.S. subsidiary RedHill Biopharma Inc. and HealthCare Royalty (“HCR”) dated February 23, 2020 (as amended) in exchange for the transfer of its rights in Movantik® (naloxegol) to Movantik Acquisition Co., an affiliate of HCR. Cravath is representing RedHill in connection with the transaction.
Deals & Cases
January 25, 2023
On January 24, 2023, WiseTech Global, developer of leading logistics execution software CargoWise, announced its acquisition of Envase Technologies (“Envase”), a leading provider of transport management system software for intermodal trucking, drayage (container haulage) and landside logistics in North America, in a transaction valued at $230 million. Envase is being acquired from private investment firm and supply chain investor Firmament, and a small number of other sellers. Cravath is representing WiseTech Global in connection with the transaction.
Publications
June 06, 2024
Cravath partner Nicholas A. Dorsey and of counsel Virginia M. Anderson co‑authored the U.S. Law & Practice chapter of the Chambers Venture Capital Guide, which was published in May 2024. The guide, which is part of the publisher’s Global Practice Guides series, provides the latest legal information on trends in the venture capital market; fund structures, economics and regulation; investments in VC companies; government subsidies and tax; and employee incentivization in the 20 jurisdictions covered. The U.S. Law & Practice chapter examined the increase in U.S. venture capital funding in artificial intelligence in 2023; the emergence of “down round” raises, bridge financing solutions and alternative financing solutions for companies that have faced financing challenges; typical venture capital fund structure in the U.S.; and more.
Firm News
November 20, 2023
On November 17, 2023, Virginia M. Anderson, D. Ana Choi, Christopher P. Davis, Janice T.P. Martindale, Flora Ng, Nicole M. Peles, Scott B. Reents and Kathryn‑Ann Stamm were named of counsels of the Firm and Jean Kearns and DongHwa Kim were named senior attorneys of the Firm, effective January 1, 2024.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.